Loading organizations...
Yanchuang Capital operates as a venture capital firm, primarily functioning as an investment and capital operation platform focused on high-tech enterprises. The firm provides strategic capital and resources to support the growth and development of innovative technology companies within its portfolio, emphasizing ventures with strong potential for market impact.
The firm was established in 2010, originating from the collaborative efforts of Peking University alumni experienced in venture capital. This foundational insight centered on leveraging academic and professional networks to identify and nurture emerging technology companies. Headquartered in Beijing, China, the firm has built its presence within the technology investment landscape.
Yanchuang Capital targets technology-driven companies seeking capital to scale operations and innovate further. The firm's long-term vision is to actively contribute to the advancement of the technology ecosystem by fostering the success of its portfolio companies, driving economic progress and technological innovation across various sectors.
Yanchuang Capital has 3 tracked investments across 3 companies. The latest tracked deal is $139.7M Series B in Avistone Pharmaceuticals in January 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 4, 2024 | Avistone Pharmaceuticals | $139.7M Series B | Guotou Chuangye, IDG Capital | Jonathan ZHU, Cathay Capital |
| May 19, 2022 | Laekna Therapeutics | $61.0M Series D | CS Capital | Infinity Capital, Worldstar |
| Mar 1, 2021 | EpimAb Biotherapeutics | $120.0M Series C | Tony Rong, Sungwon Song | Cventures, Adrian Cheng, Cormorant Asset Management, Decheng Capital, Hidragon Capital, Hony Capital, Octagon Capital, Sdic Fund, ShangBay Capital, Sherpa Healthcare Partners |
